Third-line or subsequent treatment of T-DXd for HER2-positive GC patients showed longer OS than chemotherapy (median, 12.5 vs. 8.4 months; HR for death, 0.59; 95% CI: 0.39 to 0.88; P = 0.01. Here, ERBB2 is linked to gastric cancer.